Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01220947 · ClinicalTrials.gov registry record · Phase 2

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

A Phase 2 study of Hepatitis C, Chronic, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
421
Enrollment target
20
Study locations

NCT01220947 is a Phase 2 study of Hepatitis C, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 421 participants, above the 360-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01220947, a Phase 2 study of Hepatitis C, Chronic, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
421 participants
Enrollment target
20
Study locations

Study Summary

This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus versus Pegasys and Copegus alone in treatment-naive patients with chronic Hepatitis C.

Conditions Studied

Hepatitis C, Chronic

Interventions

  • DRUG Copegus
  • DRUG Danoprevir
  • DRUG Pegasys

Study Locations (20)

California

  • - La Jolla
  • - Sacramento
  • - San Diego
  • - San Francisco

Florida

  • - Orlando
  • - Orlando
  • - South Miami

New York

  • - Manhasset
  • - New York
  • - The Bronx

North Carolina

  • - Chapel Hill
  • - Fayetteville

Colorado

  • - Aurora

Georgia

  • - Decatur

Hawaii

  • - Honolulu

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 421 participants
Start Date 2010-11
Est. Completion 2012-12
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01220947

The ClinicalTrials.gov registry entry for NCT01220947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 360-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (17% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 3 interventions - of which Copegus is the first listed.

NCT01220947 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT01220947 about?

NCT01220947 is a clinical study titled "A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection". This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus versus Pegasys and Copegus alone in treatment-naive patients with chroni...

What is the current status of trial NCT01220947?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 421 participants. The study started on 2010-11. Estimated completion is 2012-12.

What conditions does trial NCT01220947 study?

This clinical trial studies the following conditions: Hepatitis C, Chronic.

What interventions are being tested in trial NCT01220947?

The interventions under investigation include: Copegus (DRUG), Danoprevir (DRUG), Pegasys (DRUG).

Who is sponsoring clinical trial NCT01220947?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01220947 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C, Chronic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.